NEW YORK--(BUSINESS WIRE)--Crossix announced today it has added several new data partners and sources as the company continues to expand its network of connected health data. Additional Rx and medical claims data will allow an even more complete picture of the patient journey, including for specialty prescription products.
The Crossix analytics platform provides technology that connects health and non-health data for more than 300 million U.S. patients to drive greater marketing effectiveness. Data includes Rx, OTC, clinical, claims, consumer, hospital, media data, and more – all of which are protected by best-in-class privacy safeguards.
This expanded prescriptions and medical claims data will be integrated into Crossix products and analytics, including into Crossix DIFA, starting in January 2020 across all customers.
“With our recent integration with Veeva Systems, Crossix plans to accelerate investments in the growth of our data assets to deliver insights that other healthcare data and analytics providers cannot replicate,” says Asaf Evenhaim, Crossix CEO. "This enhanced data footprint will help life sciences companies better understand ever-changing patient dynamics."
About Crossix Solutions, A Veeva Company
Crossix partners with top health brands to maximize media and marketing effectiveness through robust data analytics. Fueled by our privacy-by-design, patented Crossix SafeMine™ technology, Crossix connects the industry’s most comprehensive set of health and non-health data, covering more than 300 million lives in the United States. Crossix DIFA™, our best-in-class, cloud-based platform, allows real-time measurement and optimization of complex, cross-channel media campaigns aimed at patients and healthcare professionals.
Customers include more than 200 pharmaceutical brands across the top 20 pharma companies, leading health systems, pharmacies, and other wellness brands. Crossix is headquartered in New York. For more information, visit crossix.com.
Forward-looking Statements
This release contains forward-looking statements, including expectations regarding the market demand for and acceptance of the data, analytics, software solutions, and services offered by Crossix, a Veeva company, and the results and benefits from use of such offerings. Any forward-looking statements contained in this press release are based upon Crossix’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Crossix’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Crossix and Veeva disclaim any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including whether demand for Crossix’s offerings will grow as anticipated; the competitive environment in the industry; and general market and business conditions. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in Veeva’s filing on Form 10-Q for the period ended October 31, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
